MicrobiotiX and West Africa Centre for Innovative Research and Care in Ghana Sign MoU to Advance Clinical Development of Bacteriophage Therapeutics and Combat AMR·MDR in AfricaSEOUL, South Korea, Nov. 20, 2025 (GLOBE NEWSWIRE) -- MicrobiotiX, a company specializing in the development of novel bacteriophage therapeutics, announced on the 12th of November 2025 that it has signed a memorandum of understanding (MoU) with the West Africa Centre for Innovative Research and Care (WAFCIRC), working with Komfo Anokye Teaching Hospital (KATH) and other tertiary hospitals in Ghana, to collaborate on the clinical research of bacteriophage-based therapies. The collaboration aims to lay the groundwork for the clinical validation of therapeutics targeting antimicrobial resistance (AMR) and multidrug-resistant (MDR) bacteria, while expanding treatment options for patients in African regions where access to antibiotics is limited.
MicrobiotiX Receives IND Approval for Novel Bacteriophage Drug MP101Korea’s First Bacteriophage IND Approved by the Ministry of Food and Drug Safety – Phase 1 Trial to Begin in Patients with Acute Pneumonia
MicrobiotiX Finalizes KRW 20 Billion Series B, Securing Korea's First Bacteriophage Clinical TrialAfter securing 15 billion KRW investment last October, MicrobiotiX has successfully closed an extended Series B with an additional 5 billion KRW… 2.5 billion KRW to be supported through a clinical grant awarded by the Korean Ministry of Health and Welfare
